Vor Biopharma VOR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $312.43M+227% | $321.53M+245% | $327.69M+269% | $335.37M+254% | $95.69M-1.1% | ||
| $61.09M+131% | $50.11M+79.8% | $39.3M+34.9% | $32.03M+6.2% | $26.46M-15.2% | ||
| $373.51M+206% | $371.64M+207% | $366.99M+211% | $367.4M+194% | $122.15M-4.5% | ||
| -$373.51M-206% | -$371.64M-207% | -$366.99M-211% | -$367.4M-194% | -$122.15M+4.5% | ||
| —— | —— | -$2.08B-37,725% | -$1.3B-19,438% | $3.55M-53.9% | ||
| —— | —— | -$2.45B-2,078% | -$1.66B-1,309% | -$118.6M+1.4% | ||
| —— | —— | -$148.18-1,495% | -$34.60-1,900% | -$22.45-1,168% | ||
| -$371.36M-213% | -$368.69M-214% | -$363.2M-218% | -$362.71M-199% | -$118.66M+4.5% | ||
| -$373.51M-206% | -$371.64M-207% | -$366.99M-211% | -$367.4M-194% | -$122.15M+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vor Biopharma profitable?
- Vor Biopharma is not currently profitable: it reported a net loss of $2.6B over the trailing twelve months.
- What is Vor Biopharma's earnings per share?
- Vor Biopharma's diluted EPS over the trailing twelve months is $-144.51.
- Where does Vor Biopharma's income statement data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.